Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Benzoyl peroxide proposal

This article was originally published in The Rose Sheet

Executive Summary

Benzoyl peroxide proposal: FDA extending comment period 60 days for a Feb. 17 proposed rule establishing additional labeling for all topical acne products containing benzoyl peroxide ("The Rose Sheet" Feb. 20, p. 12) to July 17, according to a May 19 Federal Register notice. FDA granted the extension after receiving a request from the Nonprescription Drug Manufacturers Association, which stated that it needed more time due to the "precedent-breaking nature of the agency's proposal," the notice says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS001642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel